A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Inclusion Criteria: * Adult participants, \>/= 18 years of age * Participants with multiple basal cell carcinomas, including participants with Gorlin syndrome, with at least 6 clinically evident basal cell carcinomas at the time of randomization, of which 3 measure 5 mm or more in diameter and are considered target lesions. All other lesions are considered to be non-target lesions * Histopathologic confirmation that at least one of the three target lesions is basal cell carcinoma * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Adequate renal and hepatic function and hematopoietic capacity * Women of childbearing potential must agree to use contraception as defined by protocol during treatment and for at least 9 months after completion of study treatment * Male participants with female partners of childbearing potential must agree to use contraception as defined by protocol during treatment and for 2 months after completion of study treatment Exclusion Criteria: * Inability or unwillingness to swallow capsules * Pregnant or breastfeeding women * Any metastatic basal cell carcinoma * Locally advanced basal cell carcinoma lesion that is considered to be inoperable or to have medical contraindications to surgery * Recent (i.e., within the past 28 days prior to randomization) or current participation in another experimental drug study * Known or suspected alcohol abuse * One of the following known rare hereditary conditions: galactose intolerance, primary hypolactasia or glucose-galactose malabsorption